Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

Company announces commencement of restructuring process supported by Highbridge Capital Management

Continued progress of launch of Omisirge^® (omidubicel-onlv), with the delivery of six units in 2023, as well as significant transplant center onboarding